Syntekabio Aiming To Be Pharma Companion In AI-Driven Drug Development

Syntekabio is at the forefront of artificial intelligence-driven new drug development in South Korea. Its CEO Tyson Kim talks to Scrip how the genome big data and AI platform company is helping the pharma industry to develop new drugs more efficiently and rapidly.

Big data
Syntekabio Pioneering AI-Driven Drug Development In Korea • Source: Shutterstock

Just several years ago, the concept of artificial intelligence (AI) sounded interesting but seemed like a technology that would only be applied in a distant future. Now it is finding applications everywhere across various industries including healthcare.

Globally, multinational pharmas like Novartis AG are increasingly adopting AI and machine learning to help drive innovation and improve efficiency. (Also see "Strategy At Novartis: Culture Change As...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Digital Technologies